Literature DB >> 32414721

Does regulating the sale of high-strength beer and cider impact hospital admissions with decompensated alcohol-related liver disease: A retrospective cohort study.

Yazan Haddadin1, Dev Katarey2, Manavi Sachdeva3, Laura Vickers3, Ishleen Kaur3, Ahmed Hashim2, Sumita Verma3.   

Abstract

OBJECTIVE: 'Sensible on Strength' (SoS), a local public health initiative, is aimed at reducing high-strength beer and cider availability. The objective of this study was to assess its impact on local hospital admissions with alcohol-related liver disease (ALD) and on drinking behaviour.
DESIGN: This was a retrospective cohort study in patients admitted with decompensated ALD, 3 years before and 3 years after the introduction of the SoS initiative.Hospital records of 143 index admissions with decompensated ALD were reviewed. Outcomes measures were the severity of liver disease on admission and mortality (inpatient and long-term), and change (if any) in alcohol drinking behaviour.
RESULTS: Comparing patients admitted in both phases, there were no significant differences in liver prognostic scores, liver-related complications, length of stay and inpatient/long-term mortality (p>0.05). However, the SoS initiative was associated with a 33% move away from beer and cider consumption (36.3% vs 54.0%; p=0.034), but without a significant change in units of alcohol consumed. The Model for End-stage Liver Disease (MELD) score was the only independent predictor of inpatient mortality (odds ratio 1.25; p=0.025).
CONCLUSION: Despite having no apparent impact on the clinical spectrum of local ALD admissions, it is conceivable that longer follow-up is needed to determine the true impact of this initiative. © Royal College of Physicians 2020. All rights reserved.

Entities:  

Keywords:  Alcohol; alcohol-related liver disease; cirrhosis; public health; regulations

Mesh:

Year:  2020        PMID: 32414721      PMCID: PMC7354022          DOI: 10.7861/clinmed.2019-0390

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  9 in total

1.  Morbidity and mortality in liver diseases in Sweden 1969-2001 in relation to alcohol consumption.

Authors:  Knut Stokkeland; Lena Brandt; Anders Ekbom; Urban Osby; Rolf Hultcrantz
Journal:  Scand J Gastroenterol       Date:  2006-04       Impact factor: 2.423

2.  Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes.

Authors:  Jennifer Guy; Marion G Peters
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-10

Review 3.  A rapid evidence review of the effectiveness and cost-effectiveness of alcohol control policies: an English perspective.

Authors:  Robyn Burton; Clive Henn; Don Lavoie; Rosanna O'Connor; Clare Perkins; Kate Sweeney; Felix Greaves; Brian Ferguson; Caryl Beynon; Annalisa Belloni; Virginia Musto; John Marsden; Nick Sheron
Journal:  Lancet       Date:  2016-12-02       Impact factor: 79.321

4.  Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK.

Authors:  Roger Williams; Graeme Alexander; Richard Aspinall; Rachel Batterham; Neeraj Bhala; Nick Bosanquet; Katherine Severi; Anya Burton; Robyn Burton; Matthew E Cramp; Natalie Day; Anil Dhawan; John Dillon; Colin Drummond; Jessica Dyson; James Ferguson; Graham R Foster; Ian Gilmore; Jonny Greenberg; Clive Henn; Mark Hudson; Helen Jarvis; Deirdre Kelly; Jake Mann; Neil McDougall; Martin McKee; Kieran Moriarty; Joanne Morling; Philip Newsome; John O'Grady; Liz Rolfe; Peter Rice; Harry Rutter; Nick Sheron; Douglas Thorburn; Julia Verne; Jyotsna Vohra; John Wass; Andrew Yeoman
Journal:  Lancet       Date:  2018-11-22       Impact factor: 79.321

Review 5.  Pricing as a means of controlling alcohol consumption.

Authors:  Anurag Sharma; Kompal Sinha; Brian Vandenberg
Journal:  Br Med Bull       Date:  2017-09-01       Impact factor: 4.291

6.  Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases.

Authors:  David W Crabb; Gene Y Im; Gyongyi Szabo; Jessica L Mellinger; Michael R Lucey
Journal:  Hepatology       Date:  2020-01       Impact factor: 17.425

Review 7.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

8.  Alcohol consumption and liver cirrhosis mortality after lifting ban on beer sales in country with state alcohol monopoly.

Authors:  Thorarinn Tyrfingsson; Sigurdur Olafsson; Einar Stefan Bjornsson; Vilhjalmur Rafnsson
Journal:  Eur J Public Health       Date:  2014-07-31       Impact factor: 3.367

9.  The relationship of alcohol sales to cirrhosis mortality.

Authors:  P J Gruenewald; W R Ponicki
Journal:  J Stud Alcohol       Date:  1995-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.